Tracleer® (bosentan)
Tracleer® (bosentan) is an oral dual endothelin receptor antagonist. Tracleer® is the only PAH therapy proven to delay disease progression, reduce severity and symptoms. Tracleer is the only oral PAH therapy with an established safety and tolerability profile in more than 80,000 patients worldwide.
US residents only: www.tracleer.com
Ventavis® (iloprost)
Ventavis® (inhaled iloprost) is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclin (PGI2) – a naturally occurring molecule that causes blood vessels to dilate, limits cellular hypertrophy, and inhibits platelet aggregation.
US residents only: www.4ventavis.com
Epoprostenol for Injection
Epoprostenol for Injection is an intravenous prostanoid vasodilator. Unlike other epoprostenol formulations approved for PAH, this formulation is stable at room temperature (77 F, 25 C), for up to 24 hours after it has been diluted and administered, making the use of frozen gel packs unnecessary.
US residents only: www.epoprostenol.com
Zavesca® (miglustat)
Miglustat, the active ingredient of Zavesca®, is an orally available molecule with a large volume of distribution, which was developed for the treatment of type 1 Gaucher disease (GD1).
US residents only: www.zavesca.com
"At Actelion I can achieve my mission to help people with unmet medical needs."
